Literature DB >> 2393260

Concentrations of oral lomefloxacin in serum and bronchial mucosa.

D R Baldwin1, D Honeybourne, J M Andrews, J P Ashby, R Wise.   

Abstract

The bronchial mucosal concentrations of lomefloxacin were determined for specimens obtained by fiber-optic bronchoscopy and compared with simultaneous concentrations in serum. The 23 patients studied were given an oral dose of 400 mg once daily for 4 days to achieve steady-state levels. The median concentration in serum was 2.5 micrograms/ml (range, 1.0 to 5 micrograms/ml), and the median bronchial mucosal concentration was 5.0 micrograms/g (range, 0.7 to 18.6 micrograms/g). The median percent penetration was 177% (range, 69 to 541%). The concentrations in serum and mucosa exceeded the MIC for 90% of strains of organisms causing bronchial infections but not sufficiently to recommend lomefloxacin for the routine treatment of pneumococcal infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393260      PMCID: PMC171749          DOI: 10.1128/AAC.34.6.1017

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  The mucosal epithelium of the respiratory tract in muco-purulent bronchitis caused by Haemophilus influenzae.

Authors:  J F HERS; J MULDER
Journal:  J Pathol Bacteriol       Date:  1953-07

Review 2.  Bronchiectasis--new therapeutic approaches based on pathogenesis.

Authors:  R A Stockley
Journal:  Clin Chest Med       Date:  1987-09       Impact factor: 2.878

3.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 4.  Bacterial colonization: pathogenesis and clinical significance.

Authors:  L B Palmer
Journal:  Clin Chest Med       Date:  1987-09       Impact factor: 2.878

5.  Antibiotic uptake by alveolar macrophages.

Authors:  J D Johnson; W L Hand; J B Francis; N King-Thompson; R W Corwin
Journal:  J Lab Clin Med       Date:  1980-03

6.  Penetration of antibiotics into the respiratory tree.

Authors:  E Bergogne-Berezin
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

7.  Penetration of piperacillin into bronchial mucosa and sputum.

Authors:  G E Marlin; K R Burgess; J Burgoyne; G R Funnell; M D Guinness
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

8.  Penetration of enoxacin into human bronchial mucosa.

Authors:  G E Marlin; P D Braude; A J Whelan; A A Somogyi
Journal:  Am Rev Respir Dis       Date:  1986-12

9.  Antibiotic entry into human polymorphonuclear leukocytes.

Authors:  R C Prokesch; W L Hand
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Membrane transport of clindamycin in alveolar macrophages.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

View more
  6 in total

Review 1.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 2.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

4.  The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.

Authors:  M Dan; K Torossian; D Weissberg; R Kitzes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 6.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.